Precision biosciences inc stock.

Find real-time DTIL - Precision BioSciences Inc stock quotes, company profile, news and forecasts from CNN Business. Precision BioSciences (DTIL Quick Quote DTIL - Free Report) has been on a downward spiral lately with significant selling pressure. After declining 27.5% over the past four weeks, the stock looks ...Nov 24, 2023 · When you look at Precision BioSciences Inc’s price-to-sales ratio at 0.93 compared to the industry median at 6.93, this company has a lower price relative to revenue compared to its peers. This could make Precision BioSciences Inc’s stock more attractive for value investors. Precision BioSciences, Inc. 302 East Pettigrew Street Suite A-100 Durham, NC 27701 United States 919 314 5512 https://www.precisionbiosciences.com Sector(s) : Healthcare Industry : Biotechnology ...Web2.40%. $1.21B. IDYA | Complete IDEAYA Biosciences Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

2.40%. $1.21B. IDYA | Complete IDEAYA Biosciences Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

On Friday, Precision Biosciences Inc [NASDAQ:DTIL] saw its stock fall -5.64% to $0.40. On the same session, the stock had its day’s lowest price of $0.3853, but rose to a high of $0.44. Over the last five days, the stock has gained 4.63%. Precision Biosciences Inc shares have fallen nearly -66.40% since the year began.DURHAM, N.C.--(BUSINESS WIRE)--Jul. 27, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced that it has received final meeting minutes from its recent Type B End of Phase 1 meeting with the U.S. Food and Drug Administration (FDA) for its lead ...

cb67aba6c16954c05dcceb4.1l1zKTVo6ersm5eXVf8wh_Dbso85lTxzWqCKCr_Iz1A.rjM0dlMnjI6PrcXmELNHw8H28PZ7_1NEPpTERcqhoRGdFwFCQh_Z2qPN3gWebAt the core of Precision Biosciences’ groundbreaking research is the ARCUS genome editing technology. This cutting-edge technology possesses unparalleled precision and versatility, enabling scientists to insert, delete, or repair disease-causing DNA in a wide range of genetic disorders. With the potential to revolutionize the field of genetic ...Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the third quarter ended September 30, 2022 and provided a business update. ... The increase in weighted average shares of common …WebInvestor Contact. Tim Kelly. (857) 702-9452. Email: [email protected]. The Investor Relations website contains information about Praxis Precision Medicines, Inc.'s business for stockholders, potential investors, and financial analysts.Nov 24, 2023 · With Precision Biosciences stock trading at $0.41 per share, the total value of Precision Biosciences stock (market capitalization) is $49.24M. Precision Biosciences stock was originally listed at a price of $17.44 in Mar 28, 2019. If you had invested in Precision Biosciences stock at $17.44, your return over the last 4 years would have been ...

Precision BioSciences, Inc. Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD’s The Liver Meeting 2023 ... Precision BioSciences Receives Approval from The Nasdaq Stock Market LLC to Transfer the Listing of its Common Stock from the Nasdaq Global Select …

DURHAM, N.C.--(BUSINESS WIRE)--Dec. 21, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing ex vivo allogeneic CAR T therapies and in vivo therapies with its ARCUS® genome editing platform, today announced that it has entered into an agreement with a syndicate of investors led by ACCELR8 to separate its wholly owned Elo Life Systems subsidiary ...

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing …Precision BioSciences, Inc. (DTIL) Stock Price, Quote, News & Analysis DTIL Precision BioSciences, Inc. Stock Price & Overview $0.37 0.0099 ( +2.79%) 3:59 …Dozens of bullish and bearish live candlestick chart patterns for the Precision BioSciences Inc stock.Mol Cancer Res. 2019;17 (2):356-369. The molecules and their uses are investigational. Arcus has not received approval from any regulatory authority for any use globally, and the safety and efficacy of these molecules has not been established. Arcus Biosciences is evaluating novel combinations of investigational medicines in early- and late ...WebIndividuals with disabilities: if you are a qualified individual with a disability and are unable or limited in your ability to use or access the online application system process due to your disability, please contact our disability applications assistant at 919-314-5512 to request assistance. Precision BioSciences provides reasonable ...

Nov 24, 2023 · When you look at Precision BioSciences Inc’s price-to-sales ratio at 0.93 compared to the industry median at 6.93, this company has a lower price relative to revenue compared to its peers. This could make Precision BioSciences Inc’s stock more attractive for value investors. Precision BioSciences Inc stock is down -74.15% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives DTIL stock a score of 34 out of a possible 100.Dec 1, 2023 · A high-level overview of Precision BioSciences, Inc. (DTIL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Precision Biosciences Inc. Watch list NEW Set a price target alert Open Last Updated: Dec 1, 2023 9:53 a.m. EST Real time quote $ 0.3645 0.0094 2.65% Previous Close …View the latest Precision Biosciences Inc. (DTIL) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS …Web

Precision BioSciences to Present at Upcoming Sidoti Conference. DURHAM, N.C., November 10, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that the Company will present at ...May 31, 2023 · In a report released today, Justin Zelin from BTIG maintained a Buy rating on Precision BioSciences ( DTIL – Research Report ), with a price target of $6.00. The company’s shares opened today ... DURHAM, N.C., November 07, 2023 -- ( BUSINESS WIRE )--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in ...Shareholders in Precision BioSciences (NASDAQ:DTIL) have lost 88%, as stock drops 11% this past week. (Simply Wall St.) Jan-09-23 07:30AM. Precision BioSciences Recaps 2022 Accomplishments and Outlines 2023 Corporate …November 7, 2023 at 4:54 AM · 3 min read. Revenues for Q3 2023 were $13.1 million, a significant increase from $7.4 million in Q3 2022. Net loss for the quarter was $8.1 million, or $ (0.07) per ...Get the LIVE share price of Precision BioSciences Inc(DTIL) and stock performance in one place to strengthen your trading strategy in US stocks.DURHAM, N.C.--(BUSINESS WIRE)--Nov. 8, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the third quarter ended September 30, 2022 and provided a business update.About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind.

Overall, Precision BioSciences Inc stock has a Value Grade of C, Growth Grade of C, Quality Grade of D, Momentum Grade of F Earnings Estimate Revisions Grade of C. Whether or not you should buy Precision BioSciences Inc stock will ultimately depend on your individual goals, risk tolerance and allocation. AAII can help you figure …Web

In addition to a $25 million equity investment from Novartis in Precision’s common stock at $2.01 per share received in June 2022, Precision received an upfront cash payment of $50 million on ...

7.24%. $256.56M. AEterna Zentaris Inc. 8.87%. $10.73M. RNA | Complete Avidity Biosciences Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Find the latest Pressure BioSciences, Inc. (PBIO) stock quote, history, news and other vital information to help you with your stock trading and investing.DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the first quarter 2023 and provide a business update on May 9, 2023.About …Get Precision BioSciences, Inc. (DTIL) real-time share value, investment, rating and financial market information from Capital. Friendly Platforms & Trading today. CFDs are …Precision Biosciences does dabble in both medical applications and food via its subsidiary, Elo Life Systems CRISPR companies are relatively richly valued (CRSP at 14.5B market cap, EDIT at 5B) whereas DTIL is only …Nov 29, 2023 · The Precision BioSciences Inc. stock price fell by -9.31% on the last day (Wednesday, 29th Nov 2023) from $0.408 to $0.370. During the last trading day the stock fluctuated 15.44% from a day low at $0.360 to a day high of $0.416. The price has risen in 6 of the last 10 days and is up by 6.78% over the past 2 weeks. Weighted average shares of common stock outstanding were approximately 110.8 million for the quarter ended September 30, 2022, as compared to approximately 59.7 million for the quarter ended September 30, 2021. ... Precision BioSciences, Inc. Condensed Consolidated Statements of Operations (In thousands, except share and per …Nov 24, 2023 · Precision Biosciences Inc (NASDAQ:DTIL)’s traded shares stood at 0.64 million during the latest session, with the company’s beta value hitting 1.50. At the last check today, the stock’s price was $0.41, to imply a decrease of -3.21% or -$0.01 in intraday trading. The DTIL share’s 52-week ...

DURHAM, N.C.--(BUSINESS WIRE)--Aug. 15, 2023-- Precision BioSciences, Inc. ... including fluctuations in our stock price, and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarterly period ended June 30, ...Precision BioSciences, Inc. 302 East Pettigrew Street Suite A-100 Durham, NC 27701 United States 919 314 5512 https://www.precisionbiosciences.com Sector(s) : Healthcare Industry : Biotechnology ...The Precision BioSciences Inc. stock price fell by -9.31% on the last day (Wednesday, 29th Nov 2023) from $0.408 to $0.370.During the last trading day the stock fluctuated 15.44% from a day low at $0.360 to a day high of $0.416.The price has risen in 6 of the last 10 days and is up by 6.78% over the past 2 weeks. Volume has increased on …DTIL founders never worried about cash until the meltdown. They hired too many PhDs, built fancy expensive labs with lots of promises. They never tried to trim ...Instagram:https://instagram. liberantradestation vs tastytradefan etfthe radical x13 ez trading computer Precision BioSciences, Inc. : DTIL Stock Price | US74019P1084 | MarketScreener. Stifel Nicolaus Adjusts Precision BioSciences Price Target to $9 …Nov 22, 2023 · Stock Price Forecast. According to 3 stock analysts, the average 12-month stock price forecast for DTIL stock stock is $3.00, which predicts an increase of 607.88%. The lowest target is $2.00 and the highest is $4.00. On average, analysts rate DTIL stock stock as a strong buy. regulated brokers for forexnyse dks Shareholders in Precision BioSciences (NASDAQ:DTIL) have lost 88%, as stock drops 11% this past week. (Simply Wall St.) Jan-09-23 07:30AM. Precision BioSciences Recaps 2022 Accomplishments and Outlines 2023 Corporate Priorities and Planned Portfolio Milestones. DURHAM, N.C.--(BUSINESS WIRE)--Nov. 3, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that an abstract on the effective cell dose and functional attributes of the company’s lead CD19 …Web humana loyalty plus reviews EVLO: Get the latest Evelo Biosciences stock price and detailed information including EVLO news, historical charts and realtime prices. Gainers Magic Empire Global Limited (NASDAQ: MEGL) shares jumped 268% to $3.42 after dropping around 8% ...List Alan, the Chief Medical Officer of Precision Biosciences Inc, sale 7,771 shares at $0.79 during a trade that took place back on Apr 27, which means that List Alan is holding 56,496 shares at $6,139 based on the most recent closing price. Stock Fundamentals for DTIL. Current profitability levels for the company are sitting at:Nov 7, 2023 · DURHAM, N.C., November 07, 2023 -- ( BUSINESS WIRE )--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in ...